Pharmacological Prerequisites for PET Ligands and Practical Issues in Preclinical PET Research
The development of PET radiopharmaceuticals for the non-invasive imaging of cancerous lesions, brain receptors, transporters and enzymes started more than 25 years ago. But till today no established algorithms exist to predict the success of a PET radiopharmaceutical. PET radioligand development is a challenging endeavor and predicting the success of PET ligand can be an elusive undertaking. A large number of PET radiopharmaceuticals have been developed for imaging, but so far only a few have found application as imaging agents in vivo in humans. Typically, the potential compound selected for development usually has the desired in vitro characteristics but unknown in vivo properties. The purpose of this chapter is to highlight some of the pharmacological constraints and prerequisites. Interspecies difference in metabolism and mass effects are discussed with examples. Finally, some of the practical issues related to laboratory animal imaging using anesthetic agents are also presented.
KeywordsPositron Emission Tomography Positron Emission Tomography Study Positron Emission Tomography Tracer Small Animal Positron Emission Tomography Positron Emission Tomography Radiotracer
Unable to display preview. Download preview PDF.
- Ametamey SM, Kessler LJ, Honer M (2006) Radiosynthesis and preclinical evaluation of [11C]-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5 (mGluR5) J Nuc Med 47:698–705Google Scholar
- Honer M, Hengerer B, Blagoev M et al. (2006) Comparison of 18F-FDOPA, 18F-FMT and 18F-FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol (in press)Google Scholar
- Hume SP, Lammertsma AA, Myers R et al. (1996) The potential of high resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Methods 15:103–112Google Scholar
- Osman S, Lundkvist C, Pike VW et al. (1996) Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand [O-methyl-11C]-WAY100635 in human and primate plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol 23:627–634PubMedCrossRefGoogle Scholar
- Pike VW, McCarron JA, Hume SP et al. (1995) Preclinical development of a radioligand for studies of central 5-HT1A receptors in vivo-[11C]-WAY100635. Med Chem Res 5:208–227Google Scholar